Understanding Clopidogrel's Interaction with CYP2C19 Inhibitors

Journal for Nurse Practitioners

Volumn 6, Issue 9, 2010, Pages 715-720

  Price, Matthew ^a   Schueler, Amy ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Angioplasty; Clopidogrel; CYP2C19; Drug interactions; FDA warning

Indexed keywords

EID: 77957663133     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2010.08.014     Document Type: Article

References (20)

1. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348(9038):1329.
2. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet 2001, 358(9281):527-533.
3. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY Study. JAMA 2005, 294:1224-1232.
4. Bhatt DL, Topol EJ Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004, 148(2):263-268.
5. Chen Z, Jiang L, Chen Y, et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: Randomised placebo-controlled trial. The Lancet 2005, 366(9497):1607-1621.
6. U.S.Food and Drug Adiministration Information for healthcare professionals: Update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC) Accessed May 5, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm.
7. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Europ Heart J 2006, 27(20):2420-2425.
8. McCance KL, Huether SE Pathophysiology: The biologic basis for disease in adults and children 2006, Elsevier Mosby, St. Louis, MO. 5th ed.
9. Cheng JW Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease. J Managed Care Pharm 2007, 13(4):326-336.
10. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006, 113(1):156-175.
11. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership Plavix Accessed May 5, 2010. http://www.plavix.com/clopidogrel.aspx.
12. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301(9):937-944.
13. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180(7):713-718.
14. Mehta SR, Yusuf S Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003, 41(4):S79-S88.
15. Gurbel PA, O'Connor CM, Cummings CC, Serebruany VL Clopidogrel: The future choice for preventing platelet activation during coronary stenting?. Pharmacol Res 1999, 40(2):107-111.
16. Chen BL, Chen Y, Tu JH, et al. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. J Clin Pharmacol 2009, 49(5):574-581.
17. Goldstein JA Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001, 52(4):349-355.
18. Quinn DI, Nemunaitis J, Fuloria J, et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkins lymphoma or multiple myeloma. Clin Pharmacokinetics 2009, 48:199-209.
19. Humphries TJ Famotidine: A notable lack of drug interactions. Scand J Gastroenterol 1987, 22(1 supp 134):55-60.
20. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20):2001-2015.